Patient characteristics and outcomes of treatment Case Age Sex Chemotherapy Surgical details 1 8 F PLADO R hepatectomy Clear margins 2 5 F VIDE R hepatectomy Clear margins Spillage 3 6 F VIDE R hepatectomy Clear margins Spillage 4 8 F Declined Partial hepatectomy Excision of part of diaphragm Residual disease 5 11 M VIDE R hepatectomy spontaneous rupture Case Additional information Follow up Status 1 15 years NED 2 21 months LTFU 3 Second look surgery: cyst 39 months NED removed 4 18 months DOD 5 Recurrence treated 12 months DOD with brachytherapy radiation PLADO = cisplatinum
and doxorubicin; VIDE = vincristine, ifosfamide, doxorubicin, etoposide; NED = no evidence of disease; LTFU = lost to follow up; DOD = died of disease.
based combination chemotherapy in patients with invasive bladder cancer: A combined analysis of two Nordic studies.
Of the resections for malignancy, 9 were for hepatoblastomas, following cisplatinum
and doxorubicin neoadjuvant chemotherapy.
In in vivo studies, the efficacy of EP-100 in comparison to saline or unconjugated CLIP 71 or cisplatinum
in an ovarian cancer xenograft model (OVCAR-3) was studied.
In view of the presence of both an adenocarcinoma and an acinic cell carcinoma at the surgical margins, she underwent 3,000 cGy of radiation therapy and 3 courses of chemotherapy with 5-fluorouracil and cisplatinum
At present, studies are comparing surgery with epirubicin, cisplatinum
, and 5-FU pre- and postoperatively because this therapy appears to be more effective than 5-FU/leucovorin alone (99).
She is currently receiving combination chemotherapy with cisplatinum
Dacarbazine, carmustine, and cisplatinum
have shown single-agent tumor responses in up to 25% of cases.
Much impetus derived from a study of 85 women within Cancer and Leukemia Group B (CALGB) involving the use of high-dose cyclophosphamide, cisplatinum
, and carmustine [Solid Tumor Autologous Marrow Transplant Program (STAMP) I regimen] as consolidation after an intensive regimen of cyclophosphamide, doxorubicin, and 5-fluorouracil in CALGB 8782 (69,70).
The partial response occurred in a 62-year-old woman with N-cadherin positive squamous cell cancer of the esophagus and lung metastases, which had been unresponsive to prior treatment with cisplatinum
and 5-fluorouracil chemotherapy, and who was subsequently treated with Exherin(TM).
The study will evaluate MORAb-009, plus the chemotherapy drugs pemetrexed and cisplatinum
, as a first-line treatment for patients with mesothelioma.
is quite reliably ototoxic, but individual sensitivity varies.